Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F15%3A%230000446" target="_blank" >RIV/00064211:_____/15:#0000446 - isvavai.cz</a>
Result on the web
<a href="http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1087508" target="_blank" >http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1087508</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1517/14656566.2015.1087508" target="_blank" >10.1517/14656566.2015.1087508</a>
Alternative languages
Result language
angličtina
Original language name
Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy
Original language description
Introduction: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo. Areas covered: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.' Expert opinion: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FO - Dermatology and venereology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXPERT OPINION ON PHARMACOTHERAPY
ISSN
1465-6566
e-ISSN
—
Volume of the periodical
16
Issue of the periodical within the volume
16
Country of publishing house
GB - UNITED KINGDOM
Number of pages
12
Pages from-to
2485-2496
UT code for WoS article
000364761200001
EID of the result in the Scopus database
—